CAR-T Therapy for Refractory Autoimmune Diseases

Summary

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19 CAR-T in the treatment of refractory autoimmune diseases.

Timeline

Start

2025-08-04

Primary completion

2026-12-31

Completion

2027-03-31

Drugs

Indications